SUMMARY
Activated phosphoinositide 3-kinase (PI3K)-AKT signaling appears to be an obligate event in the development of cancer. The highly related members of the mammalian FoxO transcription factor family, FoxO1, FoxO3, and FoxO4, represent one of several effector arms of PI3K-AKT signaling, prompting genetic analysis of the role of FoxOs in the neoplastic phenotypes linked to PI3K-AKT activation. While germline or somatic deletion of up to five FoxO alleles produced remarkably modest neoplastic phenotypes, broad somatic deletion of all FoxOs engendered a progressive cancer-prone condition characterized by thymic lymphomas and hemangiomas, demonstrating that the mammalian FoxOs are indeed bona fide tumor suppressors. Transcriptome and promoter analyses of differentially affected endothelium identified direct FoxO targets and revealed that FoxO regulation of these targets in vivo is highly context-specific, even in the same cell type. Functional studies validated Sprouty2 and PBX1, among others, as FoxO-regulated mediators of endothelial cell morphogenesis and vascular homeostasis.
INTRODUCTION
The PI3K-AKT pathway is activated in human cancers, commonly through genetic alterations of its many signaling components. AKT and the p110a catalytic subunit of PI3K is mutated or amplified and overexpressed in several cancer types, and PTEN, the key PI3K-AKT pathway antagonist, is also inactivated in a broad spectrum of human cancers (Cully et al., 2006) . Moreover, germline PTEN mutations define three related syndromes characterized by hamartomas, cancer, and developmental defects (Wanner et al., 2001 ). PTEN's diverse tumor suppressor role in different cell lineages is further evidenced by the cancer-prone condition in germline and conditional Pten mutant mice, which develop carcinomas of the skin, prostate, colon, breast, and endometrium, as well as thymic lymphomas, among other cancers (Di Cristofano et al., 1998; Li et al., 2002; Podsypanina et al., 1999; Suzuki et al., 2001; Wang et al., 2003; You et al., 2002) . In addition to a direct role in tumor development, PI3K-AKT signaling has been linked to endothelial cell (EC) homeostasis (Shiojima and Walsh, 2002) . One of the PTEN germline mutation syndromes, Bannayan-Zonana, is characterized by hemangiomas (EC hamartomas) in diverse tissues (Wanner et al., 2001) , and Pten heterozygous mice develop hemangiomas with high penetrance (Freeman et al., 2006) .
The wide range of benign to malignant phenotypes mediated by PI3K-PTEN-AKT signaling is consistent with the existence of diverse downstream effectors differentially utilized in conferring neoplastic phenotypes in distinct cell lineages. Among such potential effectors are AKT phosphorylation targets TSC2, GSK3, and the FoxOs (Brunet et al., 1999; Cross et al., 1995; Inoki et al., 2002) . Recently, much attention has been focused on TSC2 and mTOR signaling as mounting pharmacological evidence suggests that mTOR is the prime effector of the PI3K-AKT pathway, with TSC2 serving as a central node linking LKB1-AMPK and PI3K-AKT with mTOR (Hay, 2005) . Indeed, the potent anti-neoplastic impact of pharmacologic mTOR inhibition raises questions as to the relevance of other AKT targets, particularly the FoxOs, in the development of cancer. On the other hand, the FoxO effector arm controls cell number in Drosophila (Junger et al., 2003; Puig et al., 2003) , and the FoxO transcription factors mediate some of the growth and survival-promoting effects of AKT signaling in ECs (Potente et al., 2005; Skurk et al., 2004) . Therefore, the relevance of FoxO transcription factors in cancer and their roles in normal tissue homeostasis remain to be elucidated.
Whereas C. elegans and Drosophila contain a single FoxO gene (DAF-16 and dFOXO, respectively), mice and humans possess three highly related FoxO homologs (FoxO1, FoxO3, and FoxO4) with overlapping patterns of expression and transcriptional activities (Anderson et al., 1998; Biggs et al., 2001; Furuyama et al., 2000) . A fourth more distantly related mammalian FoxO family member, FoxO6, has been identified, although it appears to be regulated by distinct mechanisms and its expression is more highly restricted to the brain (Jacobs et al., 2003; van der Heide et al., 2005) .
In cell culture-based systems, FoxO1, FoxO3, and FoxO4 behave similarly in biochemical studies, appear to regulate common target genes, and bind to the same target DNA sequence (Biggs et al., 2001; Brunet et al., 1999; Furuyama et al., 2000) . Yet, mouse FoxO knockouts have revealed unique roles for the FoxOs, such as the requirement for FoxO3 in ovarian primordial follicle activation (Castrillon et al., 2003; Hosaka et al., 2004) and FoxO1 in vasculogenesis (Furuyama et al., 2004; Hosaka et al., 2004) . However, while the three FoxOs serve some discrete functions, they likely have significant redundancies, as they are broadly expressed during embryonic development and in adult tissues (Furuyama et al., 2000) . In this regard, conventional genetic analysis can fail to uncover important biological functions among closely-related gene families, such as Rb/p107/p130 (Lee et al., 1996; Sage et al., 2000) and p53/p63/p73 (Flores et al., 2002; 2005) . Indeed, many analogies can be drawn between the FoxO, Rb, and p53 gene families, all of which regulate cell survival and growth and consist of members with common physiological roles.
In the context of the linkage of FoxOs to key cancer signaling pathways, the lack of an overt tumor-prone phenotype of the various FoxO knockout mice was somewhat unanticipated (Castrillon et al., 2003; Hosaka et al., 2004; Lin et al., 2004) . While this may relate to the physical and functional relatedness and overlapping expression patterns of the FoxO members, it is formally possible that the FoxO arm of the PI3K-AKT signaling network plays a relatively minor in vivo role in cancer suppression and vascular biology relative to other AKT downstream targets. To address these issues, we have generated conditional alleles for all three FoxO members with which to conduct a systematic evaluation of FoxO family function in vivo. Table S1 in the Supplemental Data). The potential for redundancy and developmental compensation among the FoxOs, coupled with the embryonic lethality of FoxO1 deficiency (Furuyama et al., 2004; Hosaka et al., 2004) , prompted the use of the inducible Mx-Cre transgene to achieve widespread somatic FoxO deletion in adult tissues. The Mx1 promoter is activated by polyinosine-polycytidylic acid (pI-pC), and pI-pC injection at 4-5 weeks of age results in transient widespread Cre expression (Kuhn et al., 1995 (Kuhn et al., 1995) (Figure 1C ), the lymphomas display an enrichment of the null alleles for all three FoxO genes ( Figure 1C ) accompanied by a marked decrease of FoxO expression on both mRNA and protein levels ( Figures 1D  and 1E ). This and the lack of lymphomas in all other genotypes retaining at least one FoxO allele ( Figure 1A ) is consistent with the need for complete FoxO deficiency in lymphomagenesis.
RESULTS

Somatic
In addition, all Mx-Cre + mice developed a striking ageprogressive hamartomatous phenotype in the EC lineage, with widespread hemangiomas, resulting in premature death ( Figure 2A ). Hemangiomas were most exaggerated in the uterus and evident by 6-8 weeks, but greatly progressed by 30-40 weeks ( Figure 2B ). Histological examination revealed massive hemangiomas with intraluminal blood and thrombi in skeletal muscle, abdominal wall, liver, adrenal glands, bone marrow, omentum, lymph node, and skin ( Figure 2C ; Figure S7A ). The ECs in most lesions appeared benign; however, 9% of Mx-Cre + mice progressed to lethal angiosarcomas ( Figure 2C ). Labeling of ECs with fluorescein-conjugated lectin revealed significant increases in the numbers of ECs in affected organs ( Figure 2D ). This proliferative phenotype was apparent as early as 3 weeks after pI-pC injection, prior to onset of macroscopic abnormalities in these vascular beds. In contrast, ECs in the lung and kidney (where hemangiomas do not develop following documented FoxO deletion) did not show any abnormalities, even at 27 weeks after pI-pC injection, establishing tissue-context requirements for the FoxOs in vivo across this single lineage ( Figure 2D Figure S7D ). Importantly, these hemangiomatous lesions that retained either FoxO3 or FoxO4 were significantly less severe as reflected by lack of mortality prior to 50 weeks of age ( Figure 2A ). In contrast, vascular abnormalities were not detected in was observed only in mice with somatic deletion of all three FoxOs ( Figure 2A ).
Cell Biological Impact of FoxO Family Deletion
To understand how the FoxOs constrain the development of thymic lymphoma and hemangiomas, we examined the proliferative and survival profiles of thymocyte and ECs derived from young cancer-free mice. Although histologically normal (data not shown), albeit with a slight reduction in total number of thymocytes compared to Mx-Cre À controls (99,110,000 ± 13,590,000 versus 147,300,000 ± 20,950,000; n = 6 each; p = 0.0825), Mx-Cre + thymocytes exhibited altered responses to growth and death stimuli. Upon stimulation with PMA + ionomycin, Mx-Cre + thymocytes showed increased proliferation relative to Mx-Cre À controls ( Figure 3A ). Proliferative enhancement was also observed with CD3 + IL2 stimulation ( Figure 3A ). Conversely, Mx-Cre + thymocytes were more resistant to cell death stimuli such as g-irradiation and high-dose dexamethasome treatment ( Figure 3A ). These observations indicate that complete loss of FoxO gene function in thymocytes predisposes to lymphomagenesis through cell-autonomous mechanisms that enhance cellular proliferation and survival.
Taking advantage of efficient Mx-Cre-mediated recombination in ECs in all tissue compartments examined (Figure S8) (Hayashi et al., 2004; Schneider et al., 2003) and the organ-restricted hemangioma phenotype in Mx-Cre + mice, we compared the biological consequences of complete FoxO deletion in ECs from affected and unaffected vascular beds in different tissues. ECs were isolated and cultured from lung (which displayed no phenotype in vivo) and liver (which displayed prominent hemangiomatous changes) from age-matched mice. The purity of these cell preparations was >97% by flow cytometry for CD31 and immunostaining for VE-cadherin and CD31 (Figures S9A and S9B) . Efficient deletion of all three FoxO alleles was confirmed by PCR, and western blot documented absence of FoxO protein in both lung and liver ECs ( Figures S9C and S9D ). In vivo, absence of mRNA for all three FoxOs in the vasculature of lung, liver, and uterus was documented by RNA in situ hybridization (RISH) ( Figure S10 ).
Relative to Mx-Cre + lung ECs, Mx-Cre + liver ECs showed enhanced proliferative response to stimulation by VEGF and bFGF, two potent proangiogenic cytokines (Bikfalvi et al., 1997; Ferrara et al., 2003 Figure 3B ; 73% versus 17.9%, p = 0.003). A similar trend was observed with bFGF stimulation (p = 0.019; data not shown). Conversely, Mx-Cre + liver ECs were significantly less sensitive to TGF-b1, a cytokine that induces EC cytostasis through Smad (Goumans et al., 2003) , consistent with documented direct interactions between Smad and FoxO (Seoane et al., 2004) . Here, MxCre À liver ECs showed reduced survival ($60%) upon exposure to TGF-b1, whereas Mx-Cre + liver ECs were much less sensitive ( Figure 3B ). Interestingly, lung ECs were insensitive to TGF-b1 stimulation irrespective of FoxO status ( Figure 3B ). In summary, mirroring the in vivo phenotypes, FoxO-deficient liver ECs exhibited enhanced proliferative and survival potential, while FoxO-deficient lung ECs did not show detectable phenotypic alterations. That FoxO exerts these biological effects in a cell-autonomous manner is supported by the observation of a prominent hemangiomatous phenotype in skeletal muscle, which showed a lack of Mx-Cre-mediated recombination in the surrounding skeletal muscle fibers yet efficient recombination in the endothelium ( Figure S8K ).
Integrated Transcriptome and Promoter Analysis Identifies Direct FoxO Targets In Vivo
The above in vivo and in vitro phenotypic characterization shows that FoxO family functions in normal tissue et al., 1993) . Next, we reasoned that the identification of FoxO binding elements (BEs) in differentially expressed genes would provide more direct insights into FoxO's actions in the observed phenotypes. To that end, we conducted a systematic in silico analysis of the regulatory regions of these 138 genes to ascertain the presence of evolutionarily conserved FoxO consensus BEs. For each gene, the À8 kb to +2 kb region surrounding the transcription start site and the 0 to +5 kb region downstream of the transcription end site in the mouse genome was surveyed. We constructed a position-specific weight matrix (PWM) based on evolutionary conservation of canonical insulin-regulated FoxO targets (IGFBP1, G6PD, PEPCK) to characterize the FoxO binding motif (consensus = BBTRTTTTD) (D.H.C., unpublished data). Potential FoxO BEs were filtered further by cross-species conservation with two independent methodologies (Supplemental Data). BEs that could be identified in mouse, human, and at least one other species were designated as a ''3-species conserved'' BE. By requiring at least one evolutionary conserved FoxO BE predicted by both methods, we identified 21 putative direct targets of FoxO family in liver ECs, 9 of which were downmodulated and 12 upmodulated upon FoxO deletion (Table 1) . Interestingly, several of these genes are highly relevant to cancer (e.g., TCF4), vascular biology (e.g., CTGF), or both, such as ID1 and ADM, two factors known to play critical roles in EC survival and to promote angiogenesis during development and tumorigenesis (Benezra, 2001; Kato et al., 2005; Nikitenko et al., 2006 ) (see Discussion).
To validate our computational approach, we sought to document direct binding of FoxOs on predicted BEs by chromatin immunoprecipitation (ChIP) and to confirm expression modulation by quantitative RT-PCR and RISH in vitro and in vivo, respectively (Table 1 ). Figure 4 illustrates the validation of Sprouty2 as a direct FoxO target. First, using a mixture of anti-FoxO1/3/4 antibodies, DNA fragments spanning FoxO BEs from both the proximal and distal regions of Sprouty2 gene were more efficiently coimmunoprecipitated in the FoxO-expressing liver ECs versus those deficient for the FoxOs ( Figure 4B) Figure 4E ).
For the other targets, we conducted similar validation studies. By RISH, 12 of 14 randomly selected putative targets exhibited transcriptional regulation by FoxO in vivo ( Figure S11 ). Of note, Meis1 and Klf6, which did not confirm by RISH, were shown to be regulated by quantitative RT-PCR, pointing to the detection limits of RISH. Moreover, all 17 randomly selected putative targets (8 downmodulated and 9 upmodulated) showed expression modulation by quantitative RT-PCR in response to FoxO deletion in culture (data not shown; Table 1 ). Finally, all eight randomly selected putative targets (six downmodulated and two upmodulated) were validated to be true direct targets of FoxO by ChIP ( Figure S12 ). Thus, eight of eight putative targets satisfied both ChIP and expression validation (Table 1) , indicating the robustness of our integrated computational-biological approach in the identification of direct targets of FoxOs in ECs in vivo.
FoxO Activities Are Lineage-Restricted In Vivo Next, to address whether the spectrum of downstream effectors of the FoxOs are further dictated by cell type, we performed similar in silico promoter analysis on a list of 354 most differentially expressed genes in the thymocyte lineage (Table S2 ) and compared these profiles with those in ECs. Strikingly, putative direct targets transcriptionally regulated by FoxOs in thymocytes with predicted FoxO BEs were completely nonoverlapping with those in EC lineage (Table 2) . A notable FoxO target in thymocytes is p27 KIP1 (CDKN1B), one of the downregulated genes with the highest conservation score and number of 3-species BEs (see Discussion). In other words, this in silico analysis not only identified putative targets of direct FoxO regulation, but also demonstrated in molecular terms that signaling downstream of FoxO is both cell type-specific and tissue-specific within the same cell type. These molecular findings provide mechanistic insights and a potential explanation for the more restricted phenotypic impact of FoxO deletion relative to activated PI3K-AKT signaling in various organ systems.
Direct Effectors of FoxO-Regulated Endothelial Cell Homeostasis
To elucidate further the mechanistic basis of FoxO dysregulation in hemangioma development, we first focused on Sprouty2 for biological validation, as it represented the most significantly regulated gene with the highest number of conserved FoxO BEs in affected liver, but not lung, EC. Using two independent Sprouty2 shRNAs (shSpry2_1 and _2), Sprouty2 protein knockdown of 73% to 75% was documented in primary cultures of liver ECs ( Figure 5C ). Figure 5B) . Similarly, TUNEL positivity in Mx-Cre À liver ECs decreased from 19% to 7% (p < 0.01), comparable with the reduction to 5% observed in Mx-Cre + liver ECs (p < 0.01). Associated with these phenotypic changes were differential expression of CyclinD1, p15, and p21 as well as Bim following Sprouty2 knockdown by shRNA ( Figure 5D ), reinforcing the view that Sprouty2 functions as a negative regulator of EC proliferation and survival. Finally, in matrigel morphogenesis assays, Mx-Cre + liver ECs developed a more robust tube network compared with Mx-Cre À liver ECs ( Figure 5E ). Again, knockdown of Sprouty2 in Mx-Cre À liver ECs enhanced such VEGF-induced tube formation to levels approaching those of Mx-Cre + liver ECs ( Figure 5E ). Taken together, these results demonstrate that Sprouty2 plays essential roles in EC growth and tube morphogenesis and is a major effector of FoxO function in the endothelium. To assess additional contributions from other validated or putative direct FoxO targets listed in Table 1 , knockdown studies were conducted on an additional set of FoxO-upregulated genes (ADM, CTGF, MRC1, and CCRN4L) and FoxO-downregulated genes (PBX1, ID1, and BMPER). These assays revealed that PBX1 exhibited robust activities in both EC proliferation and apoptosis assays similar to Sprouty2, and two targets (CTGF and ADM) showed modest effects on EC growth but not on apoptosis ( Figure S13 ). Taking into account the technical caveat of insufficient knockdown, these functional data suggest that an additional but limited number of direct FoxO targets participate in control of EC homeostasis as well.
DISCUSSION
In this study, systematic genetic analysis provided formal proof that the FoxOs are tumor suppressors in vivo, albeit with a narrower tumor spectrum than might have been predicted from previous biochemical models but in line with inherited genetic syndromes targeting the PI3K pathway in humans. By demonstrating regulation of distinct sets of putative direct targets by FoxOs in thymocytes and ECs, this study also offers molecular insights into the highly tissue-restricted and lineage-specific actions of FoxO in vivo.
FoxO Transcription Factors Are Functionally Redundant in Tumor Suppression
The requirement for complete deletion of all three FoxO loci in lymphomas, despite mosaic deletion patterns in premalignant thymocytes, combined with the lack of an increased lymphoma incidence in Mx-Cre + animals bearing any two floxed alleles, strongly argues for extensive functional redundancy with strong selective pressure for inactivation of all three FoxOs on the level of tumor formation. With regard to the molecular basis of lymphomagenesis in the setting of FoxO deficiency, our in vitro studies suggest that increased cell cycle progression, as well as resistance to proapoptotic stimuli, account for the increased incidence of lymphomas in vivo. Consistent with this interpretation, p27 KIP1 , a known T cell lymphoma suppressor gene (Geisen et al., 2003; Kang-Decker et al., 2004; Martins and Berns, 2002) and FoxO target (Dijkers et al., 2000; Medema et al., 2000; Stahl et al., 2002) , was identified as one of the most significantly downregulated genes with a high number of evolutionarily conserved BEs. It is somewhat unanticipated that the tumor spectrum following deletion of the three FoxOs is so restricted given that misregulation of the PTEN/AKT axis results in a wide range of tumors, including carcinomas (skin, colon, prostate, etc.), which were not observed following deletion of the three FoxOs. It is unlikely that this relates to insufficient Mx-Cre activity in epithelial tissue compartments given our documentation of efficient Cre-mediated recombination by both PCR and strong reporter activation in a wide range of epithelial compartments, including skin, mammary tissue, and GI tract ( Figure S8 ). Furthermore, deletion of the FoxOs using K14-Cre, which is strongly expressed in a wide range of epithelia, did not result in epithelial hyperplasia or cancer in animals that were permitted to age normally for up to 16 months of age (D.H.C. and George John, unpublished data). At the same time, we cannot exclude the possibility that a limited number of epithelial cell types may not be targeted efficiently by Mx-Cre and do in fact depend upon FoxO tumor suppression activity, or that certain epithelia require a longer latency than the lethal neoplasias observed in our model. Such considerations gain relevance in light of FoxO1 deletions in a high percentage of human prostate cancers, although the existence of PI3K pathway mutations (e.g., PTEN) remains undetermined in those cancers with FoxO1 alterations (Dong et al., 2006) . While the lack of neoplastic phenotypes in epithelial tissues does not diminish the importance of the FoxOs in other cell lineages, our genetic analysis strongly suggests that other signaling surrogates (presumably the mTOR-S6K arm) play more prominent roles in the cancer-relevant activities of the PI3K-AKT network in most epithelial compartments, consistent with the collective data from other labs (Neshat et al., 2001) . In this regard, although relatively infrequent, lymphomas have been documented in human PTENgermline syndromes, and alterations in the PTEN gene have been reported in spontaneous lymphoid neoplasms (Sakai et al., 1998) . Moreover, mice with T cell-specific deletion of Pten uniformly develop T cell lymphomas (Suzuki et al., 2001) .
In regard to the FoxO-deficient vascular phenotype, it is interesting that hemangiomas are characteristic of human disease syndromes resulting from germline Pten mutations such as Cowden's disease and Bannayan-Zonana syndrome (Wanner et al., 2001) . Thus, the demonstration that FoxO inactivation is sufficient to drive development of hemangiomas suggests that misregulation of the FoxOs is a prime mechanism by which PTEN loss leads to hemangiomas in these patients. Along these lines, benign liver hemangiomas associated with TSC2 deficiency display nuclear FoxO due to inactivation of AKT pathway, whereas TSC2 deficiency in a Pten +/À background leads to very aggressive lethal hemangiomas wherein FoxOs localize to the cytosol (Manning et al., 2005) . Finally, such restricted cancer phenotypes following deletion of all three FoxOs reveals surprisingly tissue-specific roles for PTEN/AKT signaling surrogates in distinct lineages. These observations highlight the value of conducting in vivo genetic studies.
The FoxO Family Regulates Endothelial Cell Homeostasis
Hemangiomas occurred systemically but were most severe in the uterus, which is perhaps a consequence of the cyclic vascular remodeling that occurs in this organ (Heryanto and Rogers, 2002) . Along similar lines, it is tempting to speculate that the hemangioma-susceptible nature of the liver and muscle, but not the pulmonary vasculature, may reflect the remodeling and regenerative capacity of these organ systems in the setting of injury (e.g., hepatectomy) or physiologic stress (e.g., exercise 
Sprouty2 Is a Major Direct Target of FoxO in Endothelial Cells
The rationale for emphasizing Sprouty2 for our in-depth biological validation studies rested on the high number of predicted FoxO DNA BEs, its known functions in branching morphogenesis, and its documented, albeit poorly understood, roles in growth inhibition. While Sprouty2 is not the sole mediator of the FoxO effects on EC growth and survival (see below), our studies prove that it is a major effector, as knockdown of Sprouty2 mimicked many of the phenotypic consequences of triple FoxO deletion. The FoxO-Sprouty2 link gains further appeal in light of previous work showing that the Drosophila Sprouty homolog functions as an antagonist of receptor tyrosine kinase (RTK) signaling pathways that regulate branching morphogenesis of airways (Hacohen et al., 1998; Kramer et al., 1999) , a process with obvious parallels to vasculogenesis. Sprouty and its mammalian homologs (Sprouty1-4) are general inhibitors of RTK signaling that function by dampening the RAS-RAF-MEK pathway (Gross et al., 2001; Reich et al., 1999) . Finally, on a more speculative level, it was recently demonstrated that Sprouty2 protein contains iron-sulfur complexes and assembles into large 24 subunit particles that store electrical charge and thus could serve as intercellular redox sensors (Wu et al., 2005) . Furthermore, Sprouty2 is subject to nitrosylation by nitric oxide (NO) (Wu et al., 2005) , consistent with studies showing that forced expression of NO synthase phenocopies the Sprouty mutation in flies (Wingrove and O'Farrell, 1999) . How these provocative findings relate to RTK inhibition remain to be determined, but the link between Sprouty proteins and NO is especially intriguing, given the importance of NO as a regulator of vascular endothelium and response to hypoxia, and given the fact that endothelium is a major site of NO synthesis. Thus, many lines of evidence support the view that Sprouty2 is a critical focal point for pathways relevant to vascular biology. At the same time, despite its potent negative regulatory effect on EC growth and survival, previous analysis of Sprouty2 knockout mice did not show high incidence of hemangioma (Taketomi et al., 2005; Shim et al., 2005) . Absence of apparent hemangiomas in Sprouty2 knockout mice may therefore reflect that the FoxO null hemangioma phenotype may require the collaborative impact of additional FoxO target genes. Indeed, our functional analysis on an additional set of FoxO-target genes supports this view, pointing to important contributions of PBX1 in FoxO-regulated vascular biology in vivo ( Figure S13 ).
In summary, by utilizing the in vivo system for somatic deletion of FoxO in multiple cell lineages, which resulted in clear phenotype-genotype correlations, and by employing computational prediction of FoxO BEs, we obtained evidence that the FoxOs effect unique biological consequences in different cell or tissue contexts via modulation of distinct downstream targets. These observations should motivate further analysis of FoxO targets for the development of novel points of therapeutic intervention in cancer and vascular disease but should also emphasize that the proper deployment of such therapies requires a systematic dissection of these targets in specific lineages and of the tissue contexts of these lineages.
EXPERIMENTAL PROCEDURES
Targeting Constructs, Generation, and Analysis of Mice See Supplemental Data.
Immunohistochemistry and Immunofluorescence
Formalin-fixed, paraffin-embedded sections were used. For stains of pituitary tumors, sections were incubated with rabbit polyclonal antibodies to prolactin, GH, or ACTH (obtained through NHPP, NIDDK, and Dr. A.F. Parlow) followed by incubation with HRP-goat anti-rabbit IgG (Zymed) or with monoclonal antibodies to TSH, FSH, and LH (LabVision/Neomarkers) utilizing the Histomouse-MAX kit (Zymed). In all cases, sections were then incubated with DAB and counterstained with hematoxylin. To visualize functional vasculature, we intravenously injected deeply anesthetized mice with 100 mg FITC-labeled tomato lectin (Vector Laboratories) and perfused the hearts with 4% paraformaldehyde; tissues were then frozen in OCT medium. Images were acquired at a 0.5 mm thickness interval using a Zeiss inverted microscope (Axiovert) with automated stage, and image deconvolution was carried out with the nearest neighbor algorithm.
Thymocyte Isolation, Proliferation, and Apoptosis For analysis of thymocytes, fresh thymus was passed through a cell strainer (Becton Dickinson) in order to produce single cell suspensions for analysis, then resuspended in RPMI-1640 media containing 10% fetal calf serum. For thymocyte proliferation assays, cells were seeded in 96-well plates at 1 3 10 5 cells per well and subjected to the following conditions: no mitogen, PMA (1 ng/ml) + ionomycin (50 ng/ml), and 3 mg/ml anti-CD3e (eBioscience) + 100 U IL-2. Cells were grown for 48 hr, and pulsed with 1 mCi [3H]-thymidine (Amersham) for the last 16 hr. Incorporated [3H]-thymidine was measured using the 1450 MicroBeta Trilux Scintillation and Luminescence Counter. For analysis of apoptosis, thymocytes were plated in 12-well plates (1 3 10 6 cells per well) and treated with 5 Gy g-irradiation or 1 mM dexamethasone for 18 hr. Cell viability was determined by staining the cells with propidium iodide and performing flow cytometric analysis.
Flow Cytometric Analysis
Single cell suspensions of thymus or EC were incubated with the following monoclonal antibodies: anti-CD4 (PE-or FITC-conjugated), anti-CD8 (PE-or APC-conjugated), anti-Mac-1-FITC, anti-CD3-PE, anti-CD25-APC, anti-CD44-PE, anti-Gr-1-PE, anti-CD19-APC, and anti-CD31-FITC (all from PharMingen). Flow cytometry analysis was performed on freshly stained samples.
Isolation and Characterization of Endothelial Cells, Microarray Analysis, and FoxO DNA Binding Element Studies See Supplemental Data.
Quantitative RT-PCR Analysis RNA was harvested using Trizol (Invitrogen) and the RNeasy kit (Qiagen). RNA was treated with RQ1 RNase-freeDNase (Promega), and cDNA was prepared utilizing Superscript II Rnase H-Reverse transcriptase (Invitrogen). Quantitative RT-PCR was performed on cDNA samples utilizing the Quantitect SYBR Green PCR kit (Qiagen) and was run on the Stratagene Mx3000P. Primer sequences are available upon request.
Western Blot Analysis
Tissues and cells were lysed with RIPA buffer (20 mM Tris [pH 7.5], 150 mM NaCl, 1% Nonidet P-40, 0.5% Sodium Deoxycholate, 1 mM EDTA, 0.1% SDS) containing complete mini protease inhibitors (Roche). Western blots were performed utilizing 50 mg of lysate protein, incubated with the following antibodies: anti-FKHR(FoxO1)/AFX (FoxO4) (Cell Signaling Technology) and anti-FKHRL1(FoxO3) (Upstate Biotechnology).
Supplemental Data
The Supplemental Data for this article can be found online at http:// www.cell.com/cgi/content/full/128/2/309/DC1/.
